UroGen Pharma (URGN) Net Equity Issued and Repurchased (2017 - 2025)
UroGen Pharma's (URGN) quarterly Net Equity Issued and Repurchased came in at $31.8 million in Q4 2025, up 288.18% on a QoQ basis from $8.2 million in Q3 2025.
UroGen Pharma (URGN) Net Equity Issued and Repurchased (2017 - 2025) Analysis & Trends
UroGen Pharma (URGN) has 7 years of Net Equity Issued and Repurchased data on file, last reported at $31.8 million in Q4 2025.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $31.8 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $40.0 million (down 57.9% YoY) and the FY2025 annual result came in at $39.8 million, down 73.67% from the prior year.
- Net Equity Issued and Repurchased climbed to $31.8 million in Q4 2025, from $8.2 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $80.1 million in Q2 2024 to a low of -$4000.0 in Q2 2025.
- A 3-year average of $32.3 million and a median of $23.4 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
- The widest YoY moves for Net Equity Issued and Repurchased: up 45.34% in 2025, down 100.0% in 2025.
- Tracing URGN's Net Equity Issued and Repurchased over 3 years: stood at $67.4 million in 2023, then plunged by 77.73% to $15.0 million in 2024, then surged by 112.16% to $31.8 million in 2025.
- The last three Net Equity Issued and Repurchased figures came in at $31.8 million (Q4 2025), $8.2 million (Q3 2025), and -$4000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 31.83 Mn |
| Dec 31, 2025 | 31.83 Mn |
| Sep 30, 2025 | 8.20 Mn |
| Sep 30, 2025 | 8.20 Mn |
| Jun 30, 2025 | -4,000.00 |
| Jun 30, 2025 | -4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Sep 30, 2024 | 15.00 Mn |
| Sep 30, 2024 | 15.00 Mn |
| Jun 30, 2024 | 80.07 Mn |
| Jun 30, 2024 | 80.07 Mn |
| Mar 31, 2024 | 56.10 Mn |
| Mar 31, 2024 | 56.10 Mn |
| Sep 30, 2023 | 67.36 Mn |
| Sep 30, 2023 | 67.36 Mn |
| Sep 30, 2020 | -32,000.00 |
| Sep 30, 2020 | -32,000.00 |
| Jun 30, 2020 | 16.60 Mn |
| Jun 30, 2020 | 16.60 Mn |